Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Mojtaba Khamenei unconscious in Qom, not actually running Iran - 2Watch China's Shenzhou 22 rescue ship arrive at Tiangong space station (video)
- 3The 10 Most Famous Style Minutes on Honorary pathway
- 4Sanofi to acquire hepatitis B vaccine maker Dynavax for $2.2 billion
- 5Members of Kenya-led security mission in Haiti were involved in rapes, U.N. says
- Meet ‘NASA Mike,’ who’s done 105,000 handstands around the world
- IDF drops over 80 explosives on Tehran weapon production sites in latest strike
- One spent $20 on candy. Another paid $700 for a custom costume. Here's how Halloween costs stacked up this year.
- Zelensky confidant dismissed from further posts amid bribery scandal
- Doctor's orders: Eat ice cream, and other tips for a long and healthy life
- These men carry towers of birds through Mexico's streets. They say their tradition is dying out.
- Jasmine Crockett in, Colin Allred out: A major shakeup for Democrats in their quest to finally win a Senate seat in Texas
- How much should a kid's birthday party cost? One mom spent $190 for pizza and ice cream at a park. Another paid $2K for a playspace and goodie bags.
- UK consumer confidence plunges amid escalating Iran conflict
